Rebecca S Heist1, Mari Mino-Kenudson2, Lecia V Sequist3, Swathi Tammireddy3, Laura Morrissey3, David C Christiani4, Jeffrey A Engelman3, A John Iafrate2. 1. Department or Thoracic Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Electronic address: rheist@partners.org. 2. Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts. 3. Department or Thoracic Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts. 4. Department of Pulmonary Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
INTRODUCTION: Amplification of fibroblast growth factor receptor 1 (FGFR1) has been reported in squamous cell lung carcinoma and may be a molecular target for therapy. Little is known, however, about the clinical and demographic correlates of FGFR1 amplification. METHODS: The study is an Institutional Review Board approved retrospective analysis of 226 patients with squamous cell lung cancer seen at the Massachusetts General Hospital from 2005 to 2011. Clinical and demographic characteristics of all patients were obtained, as well as treatment details including surgery, radiation, and chemotherapy, and overall survival. fluorescence in situ hybridization was performed for FGFR1 on formalin-fixed paraffin-embedded tumor tissue. Clinical genotyping results were also reviewed where available. RESULTS: Thirty-seven of 226 patients (16%) with squamous cell lung cancer were found positive for amplification using a definition of amplification of a gene to copy number control ratio of 2.2 or higher. FGFR1 amplification status was not associated with age, sex, stage, histologic subtype within squamous cell, smoking history, or pack-years of smoking. We found no significant difference in overall survival by FGFR1 amplification status as a whole; in the advanced stage subset, our findings are inconclusive because of the small sample size. CONCLUSION: FGFR1 amplification was found in 16% of a clinical cohort of squamous cell lung cancer patients. The lack of any specific clinicodemographic features that correlates with FGFR1 amplification suggests that all squamous cell patients should be tested for this genomic change.
INTRODUCTION: Amplification of fibroblast growth factor receptor 1 (FGFR1) has been reported in squamous cell lung carcinoma and may be a molecular target for therapy. Little is known, however, about the clinical and demographic correlates of FGFR1 amplification. METHODS: The study is an Institutional Review Board approved retrospective analysis of 226 patients with squamous cell lung cancer seen at the Massachusetts General Hospital from 2005 to 2011. Clinical and demographic characteristics of all patients were obtained, as well as treatment details including surgery, radiation, and chemotherapy, and overall survival. fluorescence in situ hybridization was performed for FGFR1 on formalin-fixed paraffin-embedded tumor tissue. Clinical genotyping results were also reviewed where available. RESULTS: Thirty-seven of 226 patients (16%) with squamous cell lung cancer were found positive for amplification using a definition of amplification of a gene to copy number control ratio of 2.2 or higher. FGFR1 amplification status was not associated with age, sex, stage, histologic subtype within squamous cell, smoking history, or pack-years of smoking. We found no significant difference in overall survival by FGFR1 amplification status as a whole; in the advanced stage subset, our findings are inconclusive because of the small sample size. CONCLUSION:FGFR1 amplification was found in 16% of a clinical cohort of squamous cell lung cancerpatients. The lack of any specific clinicodemographic features that correlates with FGFR1 amplification suggests that all squamous cellpatients should be tested for this genomic change.
Authors: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: F Courjal; M Cuny; J Simony-Lafontaine; G Louason; P Speiser; R Zeillinger; C Rodriguez; C Theillet Journal: Cancer Res Date: 1997-10-01 Impact factor: 12.701
Authors: Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson Journal: N Engl J Med Date: 2006-12-14 Impact factor: 91.245
Authors: William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus Journal: Proc Natl Acad Sci U S A Date: 2004-08-25 Impact factor: 11.205
Authors: Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544
Authors: J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson Journal: Science Date: 2004-04-29 Impact factor: 47.728
Authors: Christine M Lusk; Donovan Watza; Greg Dyson; Douglas Craig; Valerie Ratliff; Angela S Wenzlaff; Fulvio Lonardo; Aliccia Bollig-Fischer; Gerold Bepler; Kristen Purrington; Shirish Gadgeel; Ann G Schwartz Journal: Clin Cancer Res Date: 2019-04-12 Impact factor: 12.531
Authors: Joshua Z Drago; Luigi Formisano; Carlos L Arteaga; Aditya Bardia; Dejan Juric; Andrzej Niemierko; Alberto Servetto; Seth A Wander; Laura M Spring; Neelima Vidula; Jerry Younger; Jeffrey Peppercorn; Megan Yuen; Giuliana Malvarosa; Dennis Sgroi; Steven J Isakoff; Beverly Moy; Leif W Ellisen; A John Iafrate Journal: Clin Cancer Res Date: 2019-08-01 Impact factor: 12.531